Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity
AuthorCho, K. H.
Pezzuto, J. M.
Bolton, J. L.
Steele, V. E.
Kelloff, G. J.
Lee, S. K.
Constantinou, Andreas I.
SourceEuropean journal of cancer
Google Scholar check
MetadataShow full item record
The present study was undertaken to determine if in vitro inhibition of one or both of the two most dominant mammalian DNA topoisomerases (topos) is common among chemopreventive agents. To determine if an agent was a topo I inhibitor, we employed the DNA relaxation and nicking assays. For potential topo II inhibitors, we used the DNA unknotting and linearisation assays. 14 of 30 agents (47%) were ineffective in all four assays (IC50 >100 μg/ml), and 11 (37%) inhibited topo II catalytic activity. The sensitivity of the topo II assay was 63%, selectivity 93%, positive predictive value 91%, and total accuracy 77%. For chemopreventive efficacy, the positive predictive value of the unknotting assay was 92%, and the total accuracy was 60%. These data suggest that reduced topo II activity is a desirable property of many known chemopreventive agents. We conclude that the unknotting assay could be a valuable addition to the in vitro tests presently used to select chemopreventive agents. Copyright (C) 2000 Elsevier Science Ltd.
Showing items related by title, author, creator and subject.
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase IIα phosphorylation Constantinou, Andreas I.; Vaughan, A. T. M.; Yamasaki, H.; Kamath, N. (1996)To explore the program of cell differentiation in Friend murine erythroleukemia (MEL) cells, we used three clonal variants: phorbol 12- myristate 13-acetate (PMA)-hypersensitive TS-19-101, PMA-resistant TR19-9, and ...
Constantinou, Andreas I.; Mehta, R.; Runyan, C.; Rao, K.; Vaughan, A.; Moon, R. (1995)Selected flavonoids were tested for their ability to inhibit the catalytic activity of DNA topoisomerase (topo) I and II. Myricetin, quercetin, fisetin, and morin were found to inhibit both enzymes, while phloretin, ...